TNNI3 and cancer: A large study encompassing 703 cancer patients, evaluated the potential of serial monitoring of cTnI at multiple intervals across chemotherapy treatments; the highest incidence of cardiotoxicity was observed in patients with elevated cTnI within 72 h of chemotherapy, which persisted one month post treatment [84].